Clinical Trial Update: Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the combination of Envafolimab, Lenavatinib, and TACE in advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Envafolimab (envafolimab)
• Lenavatinib
• TACE

Snippet

Sponsor: Zhejiang University | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED